September 2016: Deutsche, hedging and biotech rebalancing

Updated: May 9, 2019


Dear investors


Performance

The Fund was up 6.1% net of fees and costs for the month, comparing favourably to the S&P 500 (-0.1%) and the ASX 200 (0.2%).




We have engaged KPMG to verify our track record from July 2013 to June 2016.

As of September 30, 2016, the state of the portfolio was as follows:



Important contributions to the portfolio in September were as follows:


Macro

The month ended with dramatic movements in Deutsche Bank after the US Department of Justice levelled a US$14 billion fine at the bank. This was destabilising. US$14 billion doesn’t move the needle on the US debt but was certainly enough to rattle Europe’s banking system.


A few encouraging words from the Bundesbank or Merkel would have quickly calmed the situation. But the main actors are bound into the opposite position by their rhetoric and growth-destroying policies toward the Greeks, Italians, Spanish and Portuguese. There is some irony in the Germans now having their own banking problem and crisis of confidence.

The episode was a good reminder that no matter how hard an investor studies the financials of an investment bank, there’s no way to know its actual trading position and risk profile. My favourite anecdote is the Morgan Stanley trader Howie Hubler, who lost US$9 billion betting that subprime mortgages would go down. We simply don’t know how Deutsche is positioned.


We took a look at Italian equities, which are trading on after-tax earnings yields of 10%, levels that typically lead to excellent multi-year returns. So far we are holding fire – it’s too hard to invest while the EU places such consistent barriers to economic success.


Matteo Renzi planned to draw a line under Italy’s financial crisis by recapitalising the nation’s banks. However his policies were declared illegal by EU bureaucrats, and in breach of recently written arbitrary EU guidelines. The EU ruled that bond holders should lose money in any bail out. With ideology comes tragedy. In Italy’s case banking bonds are widely held by retail investors, and the situation so stressed a Roman pensioner that he hanged himself.


To make matters worse both Italy and Spain were in breach of arbitrary EU deficit rules, leading to both their Governments being Euro-slapped on the wrist. While this was seen as a positive development – there were fears the EU would punish more harshly – it’s hard to see what was achieved, or why the EU is not encouraging investment, instead of hindering it.


If a Government shrinks its deficit by firing people and backing out of financial commitments, the deficit necessarily grows in percentage terms, prompting a cycle of further sackings and broken promises. The European political structure has triggered this kind of doom loop all across the Mediterranean as a matter of principle.

These are the reasons we stayed away from the Italian trade.



Given our recent returns and the political risks highlighted by Friday’s Deutsche volatility we are far more hedged than usual. Should these trades pay off we will be well positioned to take advantage of the resulting investment opportunities.


Our diversified global portfolio of stocks combined with short market and long volatility hedges sounds as attractive as ever.


Portfolio


We made a number of changes to the portfolio.


We re-orientated our biotech positions. We sold Amgen and Abbvie and purchased a biotech ETF (IBB) with the proceeds. Both Amgen and Abbvie are brilliant companies trading at circa 10x forward EBITDA multiples, but this is common across the biotech sector and we decided this view was best expressed with a 4% industry-wide position.


Furthermore Abbvie’s dependence on Humira and a web of patents was concerning. While Amgen has an excellent Phase III pipeline we decided to take the pipeline of the industry as a whole instead. We retained our positions in Celgene, Horizon Pharma and Gilead.


We added two pharmaceutical development companies to the portfolio: bluebird bio and Bionomics. We generally won’t invest in a developing pharmaceutical company based on research pipeline alone, as such outcomes are known unknowns, and notoriously fickle. To put capital at risk we must also be convinced the company has leading expertise in a particular area of research.


A high quality research platform improves the risk/reward in such a risky sector by adding strategic value, and increasing the likelihood of a buy-out above the risk-weighted market value of the pipeline. In this case bluebird bio is a market leader in viral vector gene modification while bionomics has an extensive drug discovery platform.


There will always be majors earning >40% margins on products with imminent patent cliffs and mountains of cash (like Gilead) that need to fill their pipelines. We are moving toward a high risk/low risk barbell position in biotech: an index of the best companies and two in the development stage.


We entered a position into Navios, now at a 5% portfolio weighting after a 10% rise. This is our punchiest position and a stock that will appear on nobody’s value screen. The risk is high but there is a reasonable chance of a 4x-10x return from here. Navios Maritime (NM) is the parent shareholder of a series of dry and wet shipping, port and logistics companies.


Navios has market leading costs and the value of the equity is currently below the value of the public shareholdings. Rates in the industry are cash-flow profitable but negative on a capital basis. With debt due in 2019, we see Navios as comfortably placed to ride out the next wave of shipping distress. We may reinvest any profits into the credit.


We sold our position in Barclays for a +5% profit. Of all our Brexit purchases this was our lowest conviction. Lloyds would actually make a better UK financial as it has the strength of brand without any pretensions to being an investment bank, but we believe the post-Brexit theme is best played elsewhere, namely in our portfolio of real estate developers focussing on London and the South-West.


Short positions


We discussed two Australian ideas but unfortunately there were no shares to short. We will follow closely and see how these develop. One declares themselves the largest citrus grower in China, with no evidence save a buggy investor relations website, and no reason to have listed in Australia anyway. The other we will keep private for now.


We will look to expand the short portfolio in coming months. We plan to do this conservatively, and would not risk more than 1.5-2.5% on a position. 5 of these would improve the net exposure position of the Fund and provide opportunity for uncorrelated alpha.


The situations we’re looking for include:

- Single product companies with rising competition and negative profitability (eg GoPro)

- Companies valued on growth multiples with negative top-line performance

- Losers in winner-takes-all markets (tech is a fruitful sector for both longs and shorts here)

- Businesses with fundamentally unprofitable economics

- Roll-ups (Valeant, Surfstitch)

- Companies with excessive stock-based compensation. Some pay >20% of revenue to employees (Twitter pays 35%) and are only profitable before this is taken into account.


Hedging


The Fund’s large hedge positions cost very little over September, and we achieved some excellent entry levels into our ‘short risk’ portfolio. Despite the large exposures the contribution from these activities was small.

Implied volatility (the type you can trade) dropped precipitously the whole month. When implied volatility is low, the cost of holding the position tends to rise. This impels those who purchased protection to close their positions, driving down implied volatility further.


When hedgers are selling market makers are buying, which leads them to increase their delta-hedging. When market makers increase delta-hedging, there’s more capital buying every dip and selling every rally. This behaviour pushes realised volatility down further completing the cycle, leading to such periods as the last few weeks where markets broke records for moving barely at all, with spot VIX well below the futures curve.


Such cycles encourage risky vol-selling from the market makers themselves, and extended periods of low volatility are invariably followed by volatility storms. In this market patience tends to be rewarded. We are positioned for such a storm now, and see these flows as opportunities.


Early in the month we purchased November S&P 500 volatility at 12% and began capturing the value of US stock price movements in either direction between now and November 21.

We like this trade as there are a number of contentions dates during this period, with two more presidential debates, and the US election itself. We are aware that a Clinton victory would likely lead to further rallies, though may damage our biotech portfolio as Clinton has very publicly targeted drug pricing. We see this as unnecessary populism. Pharmaceutical development needs more investment rather than less.


A Trump victory would likely lead to a sharp increase in volatility.


Delta hedging S&P500 call options has an excellent advantage over our long VIX strategies – we are compelled to hold a substantial short positions in the S&P500 overnight. This is good for our sleep, and good for your portfolio if there’s any trouble in the Asian or early European trading sessions.


As a final note, it’s striking how many sectors of the S&P 500 are trading at the top of their valuation ranges.


Sincerely


Michael Frazis

michael@fraziscapitalpartners.com






Disclaimer

The contents of this document are communicated by, and the property of, Frazis Capital Partners. Frazis Capital Partners Limited is authorised and regulated by the Australian Securities and Investments Commission (“ASIC”).

The information and opinions contained in this document are subject to updating and verification and may be subject to amendment. No representation, warranty, or undertaking, express or limited, is given as to the accuracy or completeness of the information or opinions contained in this document by Frazis Capital Partners or its directors. No liability is accepted by such persons for the accuracy or completeness of any information or opinions. As such, no reliance may be placed for any purpose on the information and opinions contained in this document.

The information contained in this document is strictly confidential.

The value of investments and any income generated may go down as well as up and is not guaranteed. Past performance is not necessarily a guide to future performance.


 

 Contact: michael@fraziscapitalpartners.com

Frazis Capital Partners Pty Ltd is a corporate authorised representative (CAR No. 1263393) of Lanterne Strategic Investors Pty Ltd (AFSL No. 238198). The Frazis Fund is open to wholesale investors only, as defined in the Corporations Act 2001 (Cth). The Company is not authorised to provide financial product advice to retail clients and information on this website does not constitute financial product advice to retail clients.

 

The information provided on this website is for general information purposes only, and does not take into account the personal circumstances or needs of investors. The Company and its directors or employees or associates will use their endeavours to ensure that the information published on the Website is accurate as at the time of its publication.  Notwithstanding this, the Company excludes any representation or warranty as to the accuracy, reliability, or completeness of the information contained on the Website.

The past results of the Company’s investment strategy do not necessarily guarantee the future performance or profitability of any investment strategies devised or suggested by the Company.

The Company, and its directors or employees or associates, do not guarantee the performance of any financial product or investment decision made in reliance of any material on this Website. The Company does not accept any loss or liability which may be suffered by a Website user as a result of any interrupted access to the Website or otherwise as a result of accessing the Website.